Cardiopulmonary involvement in Fabry’s disease

References

• Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249–54.
   Google Scholar
• Schafer E, Baron K, Widmer U, Deegan P, Neumann HP, Sunder-Plassmann G, Johansson JO, Whybra C, Ries M, Pastores GM, Mehta A, Beck M, Gal A. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry dis-ease. Hum Mutat 2005; 25: 412.
   Google Scholar
• MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769–75.
   Google Scholar
• Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic muta-tions on clinical course. Medicine (Baltimore) 2002; 81: 122–38.
   Google Scholar
• Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 1976; 54: 818–25.
   Google Scholar
• Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol 1986; 7: 1157–61.
   Google Scholar
• Pochis WT, Litzow JT, King BG, Kenny D. Electrophysio-logic findings in Fabry’s disease with a short PR interval. Am J Cardiol 1994; 74: 203–4.
   Google Scholar
• Kariman K, Singletary WV, Jr, Sicker HO. Pulmonary involvement in Fabry’s disease. Am J Med 1978; 64: 911–2.
   Google Scholar
• Rosenberg DM, Ferrans VJ, Fulmer JD, Line BR, Barranger JA, Brady RO, Crystal RG. Chronic airflow obstruction in Fabry’s disease. Am J Med 1980; 68: 898–905.
   Google Scholar
• Bierer G, Balfe D, Wilcox WR, Mosenifar Z. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2006; 29: 572–9.
   Google Scholar
• Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G, Eng CM, Desnick RJ. Pulmonary involve-ment in Fabry disease. Am J Respir Crit Care Med 1997; 155: 1004–10.
   Google Scholar
• Desnick RJ, Ioannou YA, Eng ME. alfa-Galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly D, Valle D, editors. The metabolic and molecular bases of inher-ited disease. New York, McGraw-Hill, 2001: p. 3733–74.
   Google Scholar
• Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifesta-tions of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236–42.
   Google Scholar
• Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, Penttinen M, Knuuti J, Mononen I, Kan-tola IM. Twenty-four-month alpha-galactosidase A replace-ment therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 2008; 31: 432–41.
   Google Scholar
• Viljanen AA, Viljanen BC, Halttunen PK, Kreus KE. Pul-monary diffusing capacity and volumes in healthy adults measured with the single breath technique. Scand J Clin Lab Invest Suppl 1982; 159: 21–34.
   Google Scholar
• Arstila M, Impivaara O, Mäki J. New ergometric reference values for clinical exercise tests. Scand J Clin Lab Invest 1990; 50: 747–55.
   Google Scholar
• Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kamp-mann R, Whybra C, Miebach E, Beck M. Electrocardio-graphic signs of hypertmphy in Fabry disease-associated hyper-trophic cardiomyopathy. Acta Paediatr Suppl 2002; 91: 21–7.
   Google Scholar
• Mason JW, Ramseth DJ, Chanter DO, Moon TE, Good-man DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electro-cardiol 2007; 40: 228–34.
   Google Scholar
• Macfarlane PW, McLaughlin SC, Devine B, Yang TF. Effects of age, sex, and race on ECG interval measurements. J Electrocardiol 1994; 27 Suppl: 14–9.
   Google Scholar
• Chen CY, Chiang BN, Macfarlane PW. Normal limits of the electrocardiogram in a Chinese population. J Electrocardiol 1989; 22: 1–15.
   Google Scholar
• Schettini C, Bianchi M, Nieto F, Sandoya E, Senra H. Ambulatory blood pressure: normality and comparison with other measurements. Hypertension Working Group. Hyper-tension 1999; 34: 818–25.
   Google Scholar
• Michelsen S, Knutsen KM, Stugaard M, Otterstad JE. Is left ventricular mass in apparently healthy, normotensive men correlated to maximal blood pressure during exercise? Eur Heart J 1990; 11: 241–8.
   Google Scholar
• Koskenvuo JW, Karra H, Lehtinen J, Niemi P, Pärkkä J, Knuuti J, Hartiala JJ. Cardiac MRI: accuracy of simulta-neous measurement of left and right ventricular parameters using three different sequences. Clin Physiol Funct Imaging 2007; 27: 385–93.
   Google Scholar
• Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivanan-than MU. Normal human left and right ventricular dimen-sions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging 2003; 17: 323–9.
   Google Scholar
• Magage S, Lubanda JC, Susa Z, Bultas J, Karetova D, Dobrovolny R, Hrebicek M, Germain DP, Linhart A. Nat-ural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis 2007; 30: 790–9.
   Google Scholar
• Bierer G, Kamangar N, Balfe D, Wilcox WR, Mosenifar Z. Cardiopulmonary exercise testing in Fabry disease. Respira-tion 2005; 72: 504–11.
   Google Scholar
• Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Car-diol 2005; 96: 842–6.
   Google Scholar
• Sheth KJ, Thomas JP, Jr. Electrocardiograms in Fabry’s disease. J Electrocardiol 1982; 15: 153–6.
   Google Scholar
• Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizy-gous male patients. Clin Genet 2003; 63: 46–52.
   Google Scholar
• von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hub-ner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. An atypical variant of Fabry’s disease with man-ifestations confined to the myocardium. N Engl J Med 1991; 324: 395–9.
   Google Scholar
• Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, Ledvinova J, Belohlavek, Kral V, Dorazilova V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulat-ing hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990; 417: 449–55.
   Google Scholar
• Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D, Zeman J, Ledvinova J, Poupetova H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J2000; 139: 1101–8.
   Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
   Google Scholar
• Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, Beck M, Ramaswami U, Linhart A, Gal A, Houge G, Widmer U, Mehta A, Sunder-Plassmann G. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 2006; 19: 782–7.
   Google Scholar
• Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34: 838–44.
   Google Scholar
• Piirild P, Lindqvist A, Rytild P, Välimäki P, Sovijärvi ARA. Which reference values should be applied to people with dif-ferent ethnical backgrounds? [in Finnish]. Suom Ltitiktiril 2001; 56: 4487–92.
   Google Scholar